Chromocell Therapeutics Corp
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
PTHS$9.37+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| For the Year Ended | For the Year Ended | |
|---|---|---|
| December 31, 2023 | December 31, 2022 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(7,380,793) | $(2,458,589) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Amortization of debt discount | 188,119 | 140,430 |
| Issuance cost from shares issued on extension of bridge loan | 201,600 | — |
| Stock-based compensation | 1,733,233 | 110,146 |
| Shares issued for license | 2,225,733 | — |
| Changes in operating assets and liabilities: | ||
| Accounts payable and accrued expenses | 1,627,005 | 413,603 |
| Accrued compensation | 424,072 | 221,875 |
| Due to parent | — | 5,386 |
| Net Cash Used In Operating Activities | (981,031) | (1,567,149) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from loan payable, net of debt discount | 201,008 | — |
| Proceeds from loan payable - related party, net of debt discount | 565,928 | 100,000 |
| Proceeds from bridge loan, net of debt discount | — | 300,000 |
| Shares issued for cash | 255,412 | — |
| Net contribution from Chromocell Corporation | — | 422,173 |
| Advance from Chromocell Corporation | — | 800,050 |
| Net Cash Provided By Financing Activities | 1,022,348 | 1,622,223 |
| NET INCREASE (DECREASE) IN CASH | 41,317 | 55,074 |
| CASH AT BEGINNING OF PERIOD | 55,074 | — |
| CASH AT END OF PERIOD | $96,391 | $55,074 |
| Supplemental cash flow information: | ||
| Cash paid for income taxes | $— | $— |
| Cash paid for interest expense | $— | $— |
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||
| Fair value of shares issued in contribution agreement | $— | $1,900,000 |
| Debt discount from shares issued on extension of bridge loan | $428,400 | $— |
| Shares forfeited | $13 | $— |
CHROMOCELL THERAPEUTICS CORPORATION
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.